Clinical Trial Update: Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a preoperative immune checkpoint inhibitor in patients with primary untreated or recurrent/metastatic head and neck squamous cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21